NEXA for partners & distributors

A fast-growing market

Analysts at Morgan Stanley, Goldman Sachs and IQVIA estimate the GLP-1 market at $100-150 billion a year by 2030-2035. More than 1 billion people worldwide live with obesity.

Why NEXA

• Retatrutide: first triple agonist (GIP, GLP-1, glucagon)
• Pharmaceutical plant with 50 years of experience, 1,800 employees, supplying 150+ countries
• 99.7% purity, 49 mg measured against declared 40 mg, no degradation at 30+ °C
• Authenticity verification system on every pack
• Ready-to-use NexaPen 40 mg, one injection a week

Sales channels

• Retail - sales to end customers
• Small wholesale - supplies to smaller distributors and partners
• Clinics and hospitals - the most stable long-term channel

Get in touch

Write to support@synedica-reta.com with your country, channel and expected volume.